PT - JOURNAL ARTICLE AU - Burkholz, Scott AU - Rubsamen, Michael AU - Blankenberg, Luke AU - Carback, Richard T. AU - Mochly-Rosen, Daria AU - Harris, Paul E. TI - Increasing Cases of SARS-CoV-2 Omicron Reinfection Reveals Ineffective Post-COVID-19 Immunity in Denmark and Conveys the Need for Continued Next-Generation Sequencing AID - 10.1101/2022.09.13.22279912 DP - 2022 Jan 01 TA - medRxiv PG - 2022.09.13.22279912 4099 - http://medrxiv.org/content/early/2022/09/14/2022.09.13.22279912.short 4100 - http://medrxiv.org/content/early/2022/09/14/2022.09.13.22279912.full AB - SARS-CoV-2 has extensively mutated creating variants of concern (VOC) resulting in global infection surges. The Omicron VOC reinfects individuals exposed to earlier variants of SARS-CoV-2 at a higher frequency than previously seen for non-Omicron VOC. An analysis of the sub-lineages associated with an Omicron primary infection and Omicron reinfection reveals that the incidence of Omicron-Omicron reinfections is occurring over a shorter time interval than seen after a primary infection with a non-Omicron VOC. Our analysis suggests that a single infection from SARS-CoV-2 may not generate the protective immunity required to defend against reinfections from emerging Omicron lineages. This analysis was made possible by Next-generation sequencing (NGS), specifically of a Danish cohort with clinical metadata on both infections occurring in the same individual. We suggest that the continuation of COVID-19 NGS and inclusion of clinical metadata is necessary to ensure effective surveillance of SARS-CoV-2 genomics, assist in treatment and vaccine development, and guide public health recommendations.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:We report our analysis of the Danish COVID-19 Genome Consortium accessible through GISAID that examined individual cases of host reinfection across VOCs, including sub-lineages. https://gisaid.org/I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are contained in the manuscript. Our data and scripts (with exceptions for GISAID restrictions, but including instructions on how to download) will also be published on gitlab at https://gitlab.com/flowpharma. https://gisaid.org/